AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

The new criteria were formulated with the aim of enhancing design of clinical trials, and ultimately leading to earlier and more effective diagnosis and treatment in the clinical setting.

Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Severe and ...

Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial ...

In December 2024, Checkpoint announced that the U.S. Food and Drug Administration (“FDA”) approved UNLOXCYT TM (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous ...